Quarterly results and guidance from the drugmakers that matter.
Atossa Therapeutics reported lower third-quarter operating expenses and created a contingent value right linked to any sale of a priority review voucher it has yet to receive.
The US biotech reported a 46% overall response rate in 76 patients with platinum-resistant or refractory ovarian cancer and said a $50 million offering extends its cash runway into Q1 2028.
The US biotech says its cash of $161.4 million should fund operations into 2029 as it progresses two epilepsy-focused programmes.
The company cites stronger XIAFLEX growth and Acthar Gel performance, and plans an FDA filing for XIAFLEX in plantar fibromatosis early next year.
Arbutus reported $59.1M net income for Q3 2026, as it and Genevant widened LNP patent litigation in Japan and Canada and the FDA cleared its oral PD-L1 candidate.
The company reported Q3 2026 results for iopofosine I 131 in Waldenström macroglobulinemia, citing an 87.5% response rate in patients treated directly after BTK inhibitor therapy.
Humacyte reports Symvess sales of $1.0 million for the third quarter, plans a November dialysis sBLA, and has begun a Phase 2a coronary bypass study.
Net product sales rose 31% quarter on quarter, yet a $389.7M charge for the October settlement with United Therapeutics drove a GAAP net loss.
Protalix BioTherapeutics reported nine-month revenue of $75.6M and net income of $26.1M, while enrolment continues in its Phase 2 PRX-115 gout study.
The Israeli plasma-derived therapeutics company cites U.S. KEDRAB sales as the main driver of $152.2 million in nine-month revenue and now expects 2026 revenue of $205-208 million.
Jiade Limited's unaudited half-year accounts show revenue slipping to RMB 8.3m while general and administrative spending climbed to RMB 48.8m, including about RMB 33m of share-based pay.
The US maker of pharmaceuticals, cosmetic ingredients and medical lubricants reported Q3 2026 net income of $930,912, with Renacidin the main driver of pharmaceutical growth.
The Eversense 365 maker reported Q3 revenue of $19.6M, driven by US growth, and raised its full-year outlook to $68-70M.
The US genetic testing company held its full-year revenue guidance at $475-490 million while lowering volume and revenue growth expectations for exome and genome testing.
The portable MRI maker narrowed its quarterly loss to $6.0 million, kept 2026 revenue guidance and flagged an FDA submission for its Contrast PMR study by year-end.
Annexon's third-quarter update says its C1q inhibitor is under EMA review, a US BLA is due in Q4 2026, and ARCHER II's Month 15 primary endpoint is nearing assessment.
The US ophthalmic company held its full-year sales guidance, lowered its profit outlook to above $40 million, and brought forward its planned G-MELT NDA submission to 2026.
The oral biologics developer also reported $45.3 million in cash at the end of Q3 2026, which it expects to fund operations through at least the end of 2027.
The company now expects 2026 revenue of $337–351 million and adjusted EBITDA of $176–190 million, citing the Jazz milestone, the Theravance acquisition and the Roche ZW209 licence.
The medical device maker reported third-quarter net sales of $207.9M and an adjusted EBITDA of $26.0M, while U.S. spine sales fell 4.3%.
Mereo BioPharma says it is still consulting regulators with Ultragenyx on a setrusumab filing path, while cash of $26.1 million is expected to last into late 2027.
The US company reported $35.1M in third-quarter revenue, a net profit of $7.0M and $104.3M in cash with no debt, and said HEPZATO is now at 33 active centres.
The Simoa maker reported third-quarter revenue ahead of expectations and set out neurology assay launches, a 2027 IVD submission plan for HD-X and updated 2026 guidance.
The company completed an $86.6 million PIPE and amended its royalty and loan agreements in October, while partner Tanabe Pharma filed for Zynlonta approval in Japan.
ImmunityBio says the FDA has broadened Anktiva's indication to include papillary-only tumours, as quarterly net product revenue rose 53% to $48.7 million.
The Nasdaq-listed vaping technology company reported a year-on-year revenue decline, citing weaker European sales linked to tighter vaping regulation, while Adjusted EBITDA turned positive.
Praxis Precision Medicines reported Q3 2026 results, with FDA decisions on relutrigine and ulixacaltamide due by 27 December 2026 and 29 January 2027 respectively.
Ionis lowered its full-year Tryngolza outlook, citing slower-than-expected uptake in severe hypertriglyceridemia, while reaffirming other guidance and launching Zanvastro in Alexander disease.
The company says its 505(b)(2) filing for AXPAXLI remains on track after a September FDA meeting, with the SOL-R primary endpoint moved to Week 40.
The gene-therapy maker reported 15 patients treated since launch, an eight-site QTC network and one batch that failed its identity assay release criterion.